



## Non-Confidential Technology Disclosure

<b>Title</b>	<b>Therapeutic Alteration of Transplantable Tissues Through <i>In Situ</i> or <i>Ex Vivo</i> Exposure to RNA Interference Molecules</b>
<b>Inventor</b>	Timothy Kowalik, Ph.D., and Mark Uknis, M.D. University of Massachusetts Medical School.
<b>Description</b>	The present invention is based on the discovery of efficacious delivery of an RNAi agent to a transplantable tissue.
<b>Application</b>	Methods and compositions of the present invention minimize organ rejection, transplantation-mediated transmission of viral infection, and the triggering of apoptosis in transplanted tissues. Specifically: <ul style="list-style-type: none"><li>• RNAi agents can prevent immune-mediated rejection of transplanted tissues.</li><li>• Transplantable tissues include allografts, pancreatic beta-islet cells, etc.</li><li>• RNAi agents may be administered in vivo or ex vivo.</li><li>• RNAi agents may be ds-siRNAs, siRNAs, miRNAs, modified oligonucleotides, etc.</li></ul>
<b>Patent Status</b>	U.S. Patent Pending
<b>Licensing Status</b>	Available to License
<b>Docket</b>	UMMC 04-93
<b>Contact</b>	Anita L. Ballesteros, Ph.D. Licensing Officer (508) 856-6611; 508.856.1482 (fax) <a href="mailto:Anita.Ballesteros@umassmed.edu">Anita.Ballesteros@umassmed.edu</a>